Smarter leaders trust GlobalData

Data Insights Cell & gene therapy in pharma: corneal endothelial cell culturing

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

Novartis AG

Sumitomo Chemical Co Ltd

Astellas Pharma Inc

Daiichi Sankyo Co Ltd

View all

According to GlobalData’s Technology Foresights, which uses over 730,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

Corneal endothelial cell culturing is a key innovation area in cell & gene therapy

Culturing corneal endothelial cells is an essential technique in regenerative medicine and ophthalmology research, as it allows for the expansion of these cells for various purposes, including corneal tissue engineering and transplantation. Corneal endothelial cells are responsible for maintaining the clarity of the cornea by regulating fluid balance. Culturing corneal endothelial cells requires adherence to strict aseptic techniques to prevent contamination. Additionally, maintaining the appropriate culture conditions, growth factors, and medium composition is essential for successful cell expansion and experimentation.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 125+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of corneal endothelial cell culturing.

Key players in corneal endothelial cell culturing – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to corneal endothelial cell culturing

Astellas Pharma is one of the leading patent filers in corneal endothelial cell culturing. Astellas Pharma is a pharmaceutical company known for its research and development efforts in various therapeutic areas, including ophthalmology. The company investigates a variety of ocular cell types, including photoreceptor cells, corneal endothelial cells, and retinal ganglion cells. A clinically advanced program underway by the company is examining the use of retinal pigmented epithelium cells to improve vision in patients with age-related macular degeneration. Sumitomo Chemical and Riken are some of the other key patent filers in corneal endothelial cell culturing.

In terms of application diversity, Pandorum Technologies leads the pack, while Newcells Biotech and Pfizer stood in the second and third positions, respectively.

By means of geographic reach, Novartis held the top position, followed by Pfizer and Alnylam Pharmaceuticals.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.